NKG7在t细胞毒性和寿命中的双重作用。

IF 8.2 1区 医学 Q1 IMMUNOLOGY
Haidong Dong, Hyoungjun Ham, Whitney Barham, Ti Wen, Jacob B Hirdler, Zhiming Mao, Dallin S Ashton, Wenjing Zhang, Fabrice Lucien-Matteoni, Henrique Borges da Silva, Daniel D Billadeau
{"title":"NKG7在t细胞毒性和寿命中的双重作用。","authors":"Haidong Dong, Hyoungjun Ham, Whitney Barham, Ti Wen, Jacob B Hirdler, Zhiming Mao, Dallin S Ashton, Wenjing Zhang, Fabrice Lucien-Matteoni, Henrique Borges da Silva, Daniel D Billadeau","doi":"10.1158/2326-6066.CIR-25-0384","DOIUrl":null,"url":null,"abstract":"<p><p>The effectiveness of T cell-based immunotherapy depends on durable T-cell responses that can efficiently eliminate tumor cells. NKG7 was discovered three decades ago as a protein associated with lytic granules. However, only studies published over the past 5 years have contributed substantially to our understanding of NKG7 in T-cell biology. NKG7 has been recognized as an important T-cell functional marker in responses to immune checkpoint inhibitor therapy and in the prognosis of certain cancers. Besides its role in the generation, trafficking, and release of lytic granules, which is critical for efficient T-cell cytotoxicity against tumor cells, NKG7 has been identified as a key negative regulator of mTORC1 activity. By restraining mTORC1 activity, NKG7 promotes T-cell longevity and memory generation after infection. Importantly, NKG7 upregulation has demonstrated therapeutic potential in preclinical T-cell therapy for cancer. Collectively, NKG7 is emerging as a promising biomarker and therapeutic addition to T cell-based immunotherapies.</p>","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":"1510-1515"},"PeriodicalIF":8.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12485375/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Dual Role for NKG7 in T-cell Cytotoxicity and Longevity.\",\"authors\":\"Haidong Dong, Hyoungjun Ham, Whitney Barham, Ti Wen, Jacob B Hirdler, Zhiming Mao, Dallin S Ashton, Wenjing Zhang, Fabrice Lucien-Matteoni, Henrique Borges da Silva, Daniel D Billadeau\",\"doi\":\"10.1158/2326-6066.CIR-25-0384\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The effectiveness of T cell-based immunotherapy depends on durable T-cell responses that can efficiently eliminate tumor cells. NKG7 was discovered three decades ago as a protein associated with lytic granules. However, only studies published over the past 5 years have contributed substantially to our understanding of NKG7 in T-cell biology. NKG7 has been recognized as an important T-cell functional marker in responses to immune checkpoint inhibitor therapy and in the prognosis of certain cancers. Besides its role in the generation, trafficking, and release of lytic granules, which is critical for efficient T-cell cytotoxicity against tumor cells, NKG7 has been identified as a key negative regulator of mTORC1 activity. By restraining mTORC1 activity, NKG7 promotes T-cell longevity and memory generation after infection. Importantly, NKG7 upregulation has demonstrated therapeutic potential in preclinical T-cell therapy for cancer. Collectively, NKG7 is emerging as a promising biomarker and therapeutic addition to T cell-based immunotherapies.</p>\",\"PeriodicalId\":9474,\"journal\":{\"name\":\"Cancer immunology research\",\"volume\":\" \",\"pages\":\"1510-1515\"},\"PeriodicalIF\":8.2000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12485375/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer immunology research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/2326-6066.CIR-25-0384\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer immunology research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2326-6066.CIR-25-0384","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

基于T细胞的免疫疗法的有效性取决于持久的T细胞反应,可以有效地消除肿瘤细胞。NKG7是在30年前作为一种与溶解颗粒相关的蛋白质被发现的。然而,只有在过去5年发表的研究对我们对NKG7在t细胞生物学中的理解做出了实质性的贡献。NKG7已被认为是免疫检查点抑制剂治疗反应和某些癌症预后的重要t细胞功能标记物。NKG7除了参与裂解颗粒的产生、运输和释放(这对于t细胞对肿瘤细胞的有效细胞毒性至关重要)之外,还被确定为mTORC1活性的关键负调控因子。通过抑制mTORC1活性,NKG7促进t细胞寿命和感染后记忆的产生。重要的是,NKG7上调已在临床前t细胞治疗癌症中显示出治疗潜力。总的来说,NKG7正在成为一种有前景的生物标志物和基于T细胞的免疫疗法的治疗补充。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

A Dual Role for NKG7 in T-cell Cytotoxicity and Longevity.

A Dual Role for NKG7 in T-cell Cytotoxicity and Longevity.

A Dual Role for NKG7 in T-cell Cytotoxicity and Longevity.

A Dual Role for NKG7 in T-cell Cytotoxicity and Longevity.

The effectiveness of T cell-based immunotherapy depends on durable T-cell responses that can efficiently eliminate tumor cells. NKG7 was discovered three decades ago as a protein associated with lytic granules. However, only studies published over the past 5 years have contributed substantially to our understanding of NKG7 in T-cell biology. NKG7 has been recognized as an important T-cell functional marker in responses to immune checkpoint inhibitor therapy and in the prognosis of certain cancers. Besides its role in the generation, trafficking, and release of lytic granules, which is critical for efficient T-cell cytotoxicity against tumor cells, NKG7 has been identified as a key negative regulator of mTORC1 activity. By restraining mTORC1 activity, NKG7 promotes T-cell longevity and memory generation after infection. Importantly, NKG7 upregulation has demonstrated therapeutic potential in preclinical T-cell therapy for cancer. Collectively, NKG7 is emerging as a promising biomarker and therapeutic addition to T cell-based immunotherapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer immunology research
Cancer immunology research ONCOLOGY-IMMUNOLOGY
CiteScore
15.60
自引率
1.00%
发文量
260
期刊介绍: Cancer Immunology Research publishes exceptional original articles showcasing significant breakthroughs across the spectrum of cancer immunology. From fundamental inquiries into host-tumor interactions to developmental therapeutics, early translational studies, and comprehensive analyses of late-stage clinical trials, the journal provides a comprehensive view of the discipline. In addition to original research, the journal features reviews and opinion pieces of broad significance, fostering cross-disciplinary collaboration within the cancer research community. Serving as a premier resource for immunology knowledge in cancer research, the journal drives deeper insights into the host-tumor relationship, potent cancer treatments, and enhanced clinical outcomes. Key areas of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and insightful clinical investigations with immunological implications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信